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A B S T R A C T
Prostate cancer is a major public health problem of the male population in all the developed countries1. This non-skin
cancer is the foremost one facing man today. Prostate cancer has become the second leading cause of cancer death2. In
this study we investigated changes in the prostate carcinoma incidence and manifestation during a thirty-three years pe-
riod. The study included 1,226 cases of prostate cancer diagnosed from 1972 to 2005 in the Primorsko-Goranska County,
Croatia. The age-adjusted incidence of prostate cancer increased from 1.69 per 100,000 men annually in 1972 to 137.58
per 100,000 men annually in 2005, which is an 81.4-fold increase. The percentage of patients with bone metastases on the
first medical examination decreased from 1972 (75%) to 2005 (15%). The most of the patients with bone metastases at the
first medical examination were between 30 and 50 years old. Early detection measures, such as prostate specific antigen
testing and transrectal ultrasound guided prostate biopsy combined with the raised public awareness of the disease, most
probably resulted in an increase of incidence.
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Introduction
Prostate cancer is a major public health problem of
the male population in all the developed countries1. This
non-skin cancer is the foremost one facing man today.
Prostate cancer has become the second leading cause of
cancer death2. Prostate cancer now outnumbers the lung
cancer as the most common cancer in American men.
The incidence of clinically detected prostate cancer is in-
creasing in younger male patients3.
Despite the recent progress made in molecular biol-
ogy, the pathogenesis of prostate cancer remains poorly
understood. The biological behavior of prostate cancer is
highly unpredictable. While some patients die not from
prostate cancer, others succumb rapidly to progressive
disease1,3. The wide spectrum of biologic behavior exhib-
ited by prostate cancer poses the difficulty of predicting
the clinical course in the individual patient1,4. Attempts
to reduce mortality have mainly focused on early detec-
tion of this disease currently based on three parameters:
digital rectal examination (DRE), serum prostate-spe-
cific antigen (PSA) and transrectal ultrasound of the
prostate (TRUS), although TRUS is mainly used as a
guide for prostate biopsies1–5.
With the advent of PSA screening programs and in-
creased public awareness of the disease, the incidence of
prostate cancer has dramatically increased over the past
decade2,4–6.
The epidemiology of the prostate cancer differs de-
pending on geographic location, race, economic status,
health care, public awareness concerning the disease
etc4,7,8. The lowest rates occur in the Far East and on the
Indian subcontinent, whereas the highest in the Western
Europe, Australia and the North America. Adjusting the
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rates to age standard population the incidence rate for
prostate carcinoma was approximately from 3/100,000
men annually in China to 187/100,000 in the United
States and 378/100,000 in Jamaica where the population
is of African descent4,7,8.We also know little about risk
factors of the prostate cancer1,4. The first and the most
important step for preventing prostate cancer and im-
prove the survival after the diagnosis is to determine the
cause, risk factors and risk behaviors. To accomplish this
goal we need more detailed, long-term epidemiology stu-
dies of the prostate cancer from all over the world. In our
study we will show how the epidemiology of prostate can-
cer changes during a 33 years period (between 1972 and
2005).
Materials and Methods
The study included 1,226 cases of prostate cancer di-
agnosed from 1972 to 2005 in the Primorsko-Goranska
County, Croatia. Information used to identify prostate
cancer cases were taken from 4 urologic consulting rooms
and the Department of Urology medical records of the
Rijeka University Hospital. We have examined the medi-
cal records of all 1,226 patients with prostate cancer. All
the relevant data for each patient were stored in a com-
puter database created using Access 2002 application
(Microsoft, USA).
Incidence rates for the Primorsko-Goranska County
were computed using data from the 1971, 1981, 1991 and
2001 Croatian censuses9. Age adjustments were made us-
ing the European standard population10. Proportions of
patients with metastases, asymptomatic and symptom-
atic patients were calculated yearly. Proportions of pros-
tate cancer patients according to 3 age groups (30–50,
51–70 and 71– 95 years old) were computed for 3 periods
(1972–1984, 1985–1993 and 1994– 2005). In the period
between 1972 and 1984 transrectal ultrasonography and
PSA measurements were not used as diagnostic proce-
dures for prostate carcinoma patients. In the period be-
tween 1985 and 1993 TRUS, but not PSA, was used as a
routine diagnostic method. In the third period (1994–
2005) both TRUS and PSA were routinely used in diag-
nosing prostate cancer. Proportions of prostate cancer
patients with metastases according to 3 age groups (30–
50, 51–70 and 71–95 years old) were computed for the
same 3 periods.
The University Hospital of Rijeka with its Depart-
ment of Urology and 4 urologic consulting rooms is the
only medical center providing health care for all urologic
patients in the Primorsko-Goranska County.
Primorsko-goranska County (2001 population: 347,235)
lies at the Croatian Adriatic coast 200 km east of Venice
(Italy) with 75% of its population residing in Rijeka, the
county seat. In 2001 the population had 49% men, of




















































































































Fig. 1. Age-standardized incidence rate (European standard population) of prostate cancer patients in the



























































































































Fig. 2. Percentage of prostate cancer patients with bone metastases at the first medical examination, from 1972 to 2005.
whom 11% were over 65 years old. The population is
largely middle class, with approximately 55% of the adult
population having graduated from secondary school. The
most of the economy is based on tertiary activities: tour-
ism and transport9.
Statistical analysis
Commercial software, Statistica 6.1 (StatSoft., Inc.,
Tulsa, OK, USA), was used for statistical analysis. Pro-
portions ware compared statistically using either the ÷2
test or Fischer’s exact test. The Mantel-Haenszel 1-de-
gree of freedom correlation was used to test for the pres-
ence of a linear trend in proportions by year, p<0.05 was
considered statistically significant.
Results
There were 1,226 Primorsko-Goranska County men
with the first diagnosis of prostate cancer made in the pe-
riod from 1972 to 2005. The age-adjusted incidence of
prostate cancer increased from 1.69 per 100,000 men an-
nually in 1972 to 137.58 per 100,000 men annually in
2005, a 81.4-fold increase. There is a significant increase
in prostate cancer incidence in 1985, 1994 and 2001
(Figure1). The percentage of patients with bone meta-
stases at the first medical examination decreased from
1972 (75%) to 2005 (15%) (p<0.05, Figure 2). The per-
centage of asymptomatic patients increased during the
same period of time.
The highest percentage of patients with the first diag-
nosis of prostate cancer in the period from 1972 to 1984
was between 71 and 90 years old. The same relation re-
mand in the period from 1985 to 1993. Between 1994 and
2005 the highest percentage of patients with prostate
cancer was between 51 and 70 years old (p<0.05, Figure 3).
In all three periods (1972–1984, 1985–1993, 1994–
2005) the highest percentage of patients with bone meta-
stases at the first medical examination was between 30
and 50 years old (p<0.05, Figure 4).
The youngest patient with the first diagnosis of pros-
tate cancer was 42 years old and the oldest one was 90
years old.
Discussion and Conclusion
Our results are clearly showing that the age adjusted
incidence rate of prostate carcinoma patients was in-
creasing during the period from 1972 to 2005. The per-
centage of prostate carcinoma patients with bone meta-
stases at the first medical examination was decreasing
during the same period of time (from 75% to 10%). The
percentage of asymptomatic patients was increasing. We
have also shown that the incidence of prostate carcinoma
patients in the period from 1994 to 2005 was higher in
the age group between 51 and 70 years, and in the peri-
ods from 1972 to 1984 and from 1985 to 1993 the inci-
dence was higher in the age group between 71 and 90
years. In all the time periods that we have examined the
percentage of patients with bone metastases at the first
medical examination was the highest in the youngest age
group between 30 and 50 years. The increase of prostate
carcinoma incidence during the examined 31 years can
be mostly justified by the introduction of new diagnostic
methods. The first significant increase of the incidence
occurred in the 1985 with the beginning of TRUS use as
diagnostic methods. The second increase occurred in the
1994 with the introduction of PSA measurement in the
diagnostic algorithm. A similar finding was observed in
the USA. The introduction of PSA testing in 1987 re-
sulted in an enormous increase in the reported incidence
of prostate cancer3,6. It is known that the PSA test de-
tects prostate cancer at an early stage in many cases3,4,6.
From 1987 the PSA has been increasingly used for diag-
nostic purposes3,6. At the beginning PSA was used in
5.1% and in 1994 in 60.6% of all newly diagnosed pros-
tate carcinomas3,6,7.




















30–50 years old prostate cancer patients
51–70 years old prostate cancer patients
71–100 years old prostate cancer patients
Fig. 3. Percentage of prostate carcinoma patients according to 3
time periods (1972–1984, 1985–1993 and 1994–2005) and 3 age



















30–50 years old patients with prostate
cancer bone metastases
51–70 years old patients with prostate
cancer bone metastases
71–100 years old patients with prostate
cancer bone metastases
Fig. 4. Percentage of patients with bone metastases on the first
medical examination according to 3 time periods (1972–1984,
1985–1993 and 1994–2005) and 3 age groups (30–50, 51–70 and
71–90 years old).
The raised public awareness of the disease in the com-
munity can also increase the incidence rate3,4,6,7. We have
found very interesting and remarkable increase of the in-
cidence occurring in 2001 and 2002. In those years we
didn’t introduce any new diagnostic methods. We have,
however, performed in the collaboration with family doc-
tors of the Primorsko-Goranska County a large action of
informing 40 years and older men of the necessity of reg-
ular urological examinations (1 per year) in order to detect
prostate cancer in early stage. The success of this action
and a higher number of examinations in our consulting
rooms were the most probable causes of this incidence in-
crease.
There is wide variation in the incidence of prostate
cancer around the world with a general raising pat-
tern3–8. The incidence of prostate cancer in the southeast
England has also increased markedly over the last 20
years5.
In the Primorsko-Goranska County in the period from
1972 to 1993 about 60% of patients with newly diagnosed
prostate carcinoma were between 71 and 90 years old.
From 1994 to 2005 60% of patients were between 51 and
70 years old. The median age at the moment of diagnos-
ing prostate cancer has been decreasing in the United
States SEER registry since 19753,4,11. In the southeast
England the rising trend in incidence was seen in all age
groups over 50 years. The decline has been mostly no-
ticed in the older age groups from 19965. We can specu-
late about two main reasons why the prostate cancer was
diagnosed mostly in the younger age group in the last pe-
riod of our study rather then in the previous two periods.
In the period from 1994 to 2005 the common use of PSA
made the diagnostic protocol more sensitive. Moreover the
awareness of prostate cancer problem in general popula-
tion was significantly higher. Therefore, the number of ex-
aminations in younger asymptomatic patients was higher.
The increased sensitivity of diagnostic protocol (TRUS
and PSA) made possible to diagnose prostate carcinoma
in its earlier stages, so the percentage of prostate carci-
noma patients with bone metastases at the first medical
examination was decreasing all through the years from
75% in 1972 to 10% in 2005.
The biological aggressiveness of prostate cancer diag-
nosed in younger patients resulted with the highest per-
centage of the bone metastases in the youngest age group
between 30 and 50 years in all the three periods of time.
It is clear that the recorded incidence of prostate can-
cer is rising in many developed countries including Croa-
tia. Early detection measures, such as prostate specific
antigen testing and transrectal ultrasound guided pros-
tate biopsy combined with the raised public awareness of
the disease, have been shown to result most probably in
an increase of incidence but also they caused the de-
crease of the median age at the moment of diagnosing
prostate cancer and the decrease of the ratio of prostate
carcinoma patients with bone metastases at the first
medical examination. The biological aggressiveness of
prostate cancer diagnosed in younger patients resulted
with the highest percentage of the bone metastases in
the youngest age group.
We still can’t be certain that despite the apparent
changes in incidence, the true disease occurrence re-
mains the same. In order to respond and clarify this un-
certainty further investigations and epidemiology moni-
toring of prostate cancer incidence should be performed.
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EPIDEMIOLOGIJA KARCINOMA PROSTATE U MEDITERANSKOJ POPULACIJI HRVATSKE –
TRIDESETTROGODI[NJA RETROSPEKTIVNA STUDIJA
S A @ E T A K
Karcinom prostate je vode}i javno-zdravstveni problem mu{ke populacije u razvijenim zemljama1. Ovo je naj~e{}i
`ljezdani rak u dana{njeg mu{karca. Karcinom prostate postao je drugi naj~e{}i uzrok smrti me|u malignim bolesti-
ma2. U ovoj studiji prou~ili smo incidenciju i manifestaciju karcinoma prostate u razdoblju od protekle 33 godine. Studi-
ja je obuhvatila 1226 slu~ajeva karcinoma prostate dijagnosticiranih u razoblju od 1972 do 2005 godine u Primorsko-
goranskoj `upaniji u Republici Hrvatskoj. Dobno prilago|ena incidencija karcinoma prostate rasla je od 1.69 na 100000
mu{karaca godi{nje 1972. do 137.58 na 100000 mu{karaca godi{nje 2005 godine, {to je porat od 81.4 puta. Postotak
bolesnika s ko{tanim metastazama dijagnosticiranim kod prvog lije~ni~kog pregleda pao je sa 75% (1972 godine) na
15% (2005 godine). Ve}ina bolesnika s ko{tanim metastazama kod prvog pregleda bila je stara izme|u 30 i 50 godina.
Metode ranog otkrivanja, kao {to je prostata specifi~ni antigen i transrektalna, ultrazvukom vo|ena, iglena biopsija
prostate u kombinaciji s povi{enom razinom javne svijesti o nu`nosti preventivnih pregleda, vjerojatni je uzrok pove-
~anja incidencije karcinoma prostate.
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